ADRX stock news today

TD Cowen starts Adarx Pharmaceuticals coverage with Buy rating

TD Cowen began covering Adarx Pharmaceuticals and assigned a Buy rating to the stock. The initiation is an analyst action and does not include a disclosed price target.

JP Morgan starts Adarx Pharmaceuticals at Overweight, $38 price target

JP Morgan began covering Adarx Pharmaceuticals with an Overweight rating. The firm set a price target of $38 per share.

UBS Starts Adarx Pharmaceuticals at Buy, $35 Price Target

UBS began covering Adarx Pharmaceuticals with a Buy rating and set a $35 price target on the stock.

Morgan Stanley starts Adarx Pharmaceuticals coverage with Overweight rating, $32 target

Morgan Stanley began covering Adarx Pharmaceuticals and assigned an Overweight rating. The firm set a price target of $32 per share.

Cowen & Co. started coverage of ADRX with a Buy rating.

UBS started coverage of ADRX with a Buy rating and a price target of $35.

Morgan Stanley started coverage of ADRX with an Overweight rating and a price target of $32.

This is a public filing with the U.S. Securities and Exchange Commission.

What is the latest news on ADRX?

Oct 20, 2026: TD Cowen starts Adarx Pharmaceuticals coverage with Buy rating (Benzinga) · Oct 20, 2026: JP Morgan starts Adarx Pharmaceuticals at Overweight, $38 price target (Benzinga) · Oct 20, 2026: UBS Starts Adarx Pharmaceuticals at Buy, $35 Price Target (Benzinga)

What are analysts saying about ADRX?

Oct 20, 2026: Cowen & Co. started coverage of ADRX with a Buy rating. · Oct 20, 2026: UBS started coverage of ADRX with a Buy rating and a price target of $35. · Oct 20, 2026: Morgan Stanley started coverage of ADRX with an Overweight rating and a price target of $32.

What has ADRX filed with the SEC recently?

Sep 24, 2026: ADARx Pharmaceuticals, Inc. filed Form S-1MEF with the SEC